SK Bio-Pharmaceuticals Drug Program is Granted Funding Support From Korean Government
SEOUL, South Korea--(BUSINESS WIRE)--The South Korean pharmaceutical company, SK Biopharmaceuticals, announced that YKP10811, for the treatment of chronic idiopathic constipation, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next two years. An agreement between the two parties was signed on December 13.